Pharmacology of Selumetinib for treatment of Neurofibromatosis-1 (New Drug 2020)

Pharmacology of Selumetinib for treatment of Neurofibromatosis-1 (New Drug 2020)

MOA – MEK 1/2 or Mitogen Activated Protein Kinase 1/2 inhibitor

Use: Neurofibromatosis-1 which is symptomatic/inoperable

Effect: Selumetinib decreases size and number of neurofibromas.

Route – Oral

Dose – 25 mg/m2 on empty stomach

Side-effects:
GIT – N/V, Diarrhoea
Rhabdomyolysis
Ocular toxicity
Cardiomyopathy